Effects of vitamin E and sesamin on hypertension and cerebral thrombogenesis in stroke-prone spontaneously hypertensive rats.
The preventive effects of sesamin, a lignan from sesame oil and vitamin E on hypertension and thrombosis were examined using stroke-prone spontaneously hypertensive rats (SHRSP). Animals at 5 weeks of age were separated into four groups: (i) control group; (ii) vitamin E group, which was given 1000 mg alpha-tocopherol/kg diet; (iii) sesamin group, given 1000 mg sesamin/kg diet; and (iv) vitamin E plus sesamin group, given 1000 mg alpha-tocopherol plus 1000 mg sesamin/kg diet for 5 weeks from 5 to 10 weeks of age. Resting blood pressure was measured by the tail-cuff method once weekly. A closed cranial window was created in the right parietal bone of the rat and platelet-rich thrombi were induced in vivo using a helium-neon laser technique. The number of laser pulses required for formation of an occlusive thrombus was used as an index of thrombotic tendency. In control rats, systolic blood pressure and the amount of urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) became significantly elevated with age. However, the elevation in blood pressure and 8-OHdG were significantly suppressed in rats administered vitamin E, sesamin, or vitamin E plus sesamin. At 10 weeks, the number of laser pulses required to induce an occlusive thrombus in arterioles of the control group was significantly lower than in the other groups (P < 0.05). These results indicate that chronic ingestion of vitamin E and sesamin attenuated both elevation in blood pressure, oxidative stress and thrombotic tendency, suggesting that these treatments might be beneficial in the prevention of hypertension and stroke.
Noguchi
Takanori
T
Human Nutrition, Kobe Gakuin University, Nishi, Kobe, Japan. noguchi@nutr.kobegakuin.ac.jp
Ikeda
Katsumi
K
Sasaki
Yasuto
Y
Yamamoto
Junichiro
J
Yamori
Yukio
Y
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000652:urine; D004149:Dioxoles / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D020767:Intracranial Thrombosis / Q000517:prevention & control*; D017705:Lignans / Q000627:therapeutic use*; D051381:Rats; D011918:Rats, Inbred SHR; D020521:Stroke / Q000517:prevention & control; D014810:Vitamin E / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D000975:Antioxidants; D004149:Dioxoles; D005343:Fibrinolytic Agents; D017705:Lignans; D014810:Vitamin E; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine; C054125:sesamin